The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Feb. 24, 2004

Filed:

Feb. 08, 2001
Applicant:
Inventors:

Benjamin Oshlack, New York, NY (US);

Curtis Wright, Nowalk, CT (US);

J. David Haddox, Upper Stepney, CT (US);

Assignee:

Euro-Celtique, S.A., Luxembourg, LU;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/20 ; A61K 9/48 ; A61K 9/00 ; A61K 9/14 ; A61K 9/16 ;
U.S. Cl.
CPC ...
A61K 9/20 ; A61K 9/48 ; A61K 9/00 ; A61K 9/14 ; A61K 9/16 ;
Abstract

Disclosed is an oral dosage form comprising (i) an opioid agonist in releasable form and (ii) a sequestered opioid antagonist which is substantially not released when the dosage form is administered intact, such that the ratio of the amount of antagonist released from said dosage form after tampering to the amount of said antagonist released from said intact dosage form is about 4:1 or greater, based on the in-vitro dissolution at 1 hour of said dosage form in 900 ml of Simulated Gastric Fluid using a USP Type II (paddle) apparatus at 75 rpm at 37 degrees C. wherein said agonist and antagonist are interdispersed and are not isolated from each other in two distinct layers.

Published as:
CA2400567A1; WO0158447A1; WO0158451A1; AU3687601A; AU3687701A; NO20023728D0; NO20023729D0; KR20020071032A; KR20020073542A; NO20023728L; NO20023729L; BR0108380A; BR0108379A; CZ20022706A3; EA200200840A1; SK11342002A3; MXPA02007686A; EP1299104A1; HUP0204229A2; HUP0204163A2; BG106986A; CN1418098A; CN1423559A; JP2003522144A; JP2003522146A; US2003143269A1; HK1051487A1; EE200200437A; US6696088B2; HK1056822A1; EP1299104A4; US2004092542A1; PL358088A1; MXPA02007690A; EA004876B1; AU776666B2; AU776904B2; US2004186121A1; US2005095291A1; US2005181046A1; NZ520554A; GEP20053614B; YU58902A; HUP0204229A3; KR100552038B1; US2006039970A1; OA12215A; AP1665A; UA79069C2; NO324717B1; TWI292317B; CA2400567C; JP2008019280A; IL151057A; PT1255547E; US2008306104A2; US2008305167A2; US2008311199A2; US2008311198A2; CZ299991B6; EP1299104B1; ATE431145T1; EE05171B1; DE60138706D1; JP2009138007A; PT1299104E; DK1299104T3; EP2092936A2; ES2326730T3; EP2092936A3; SI1299104T1; CN100563656C; SK287107B6; RS50407B; US7658939B2; BG65828B1; US7682632B2; CN101703777A; US7718192B2; HK1135907A1; US7842311B2; US7842309B2; EP2277521A1; EP2283842A1; US2011097404A1; ME00398B; MEP48308A; IL181356A; IL204761A; PL210845B1; US8236351B2; JP2012158592A; JP2012176993A; EP2517710A1; US2012288565A1; CN101703777B; US8357399B2; EP2092936B1; DK2092936T3; PT2092936E; ES2415407T3; SI2092936T1; US2013251789A1; US8586088B2; JP5351538B2; US2014099369A1; HU229705B1; CY1109270T1; JP2014169306A; US8936812B2; JP5676504B2; JP2015044838A; EP2277521B1; EP2283842B1; EP2517710B1; DK2277521T3; DK2283842T3; DK2517710T3; PT2277521E; PT2283842E; PT2517710E; US2015182467A1; ES2539904T3; ES2539945T3; ES2540103T3; SI2277521T1; SI2283842T1; SI2517710T1; US2015231086A1; US9278073B2; CY1114063T1; US9456989B2; JP2016222730A; JP6063427B2; EP3130338A1; JP2017048210A; US2017119685A1; US9801828B2; US2018042859A1; BRPI0108380A8; JP6403742B2; US10350173B2; BRPI0108380B1; US2019350868A1; US10588865B2; BRPI0108380B8;

Find Patent Forward Citations

Loading…